PROPAFENONE HCL- propafenone hydrochloride tablet, film coated United States - English - NLM (National Library of Medicine)

propafenone hcl- propafenone hydrochloride tablet, film coated

mckesson corporation dba sky packaging - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg - propafenone hydrochloride is indicated to: - prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms in patients without structural heart disease. - prolong the time to recurrence of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms in patients without structural heart disease. - treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. initiate treatment in the hospital. usage considerations: - the use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (af) or in patients exclusively with atrial flutter or psvt has not been evaluated. do not use propafenone hydrochloride tablets to control ventricular rate during af. - some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the 

PROPAFENONE HCL- propafenone hydrochloride tablet, film coated United States - English - NLM (National Library of Medicine)

propafenone hcl- propafenone hydrochloride tablet, film coated

a-s medication solutions - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 225 mg - propafenone hydrochloride is indicated to: - prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms in patients without structural heart disease. - prolong the time to recurrence of paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms in patients without structural heart disease. - treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. initiate treatment in the hospital. usage considerations: - the use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (af) or in patients exclusively with atrial flutter or psvt has not been evaluated. do not use propafenone hydrochloride tablets to control ventricular rate during af. - some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the 

PROPAFENONE HYDROCHLORIDE- propafenone hydrochloride tablet, film coated United States - English - NLM (National Library of Medicine)

propafenone hydrochloride- propafenone hydrochloride tablet, film coated

a-s medication solutions - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 225 mg - propafenone hydrochloride tablets are indicated to: usage considerations: propafenone hydrochloride tablets are contraindicated in the following circumstances: pregnancy category c. there are no adequate and well-controlled studies in pregnant women. propafenone hydrochloride tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. animal data: teratogenic effects: propafenone has been shown to be embryotoxic (decreased survival) in rabbits and rats when given in oral maternally toxic doses of 150 mg/kg day (about 3 times the maximum recommended human dose [mrhd] on a mg/m2 basis) and 600 mg/kg/day (about 6 times the mrhd on a mg/m2 basis), respectively. although maternally tolerated doses (up to 270 mg/kg/day, about 3 times the mrhd on a mg/m2 basis) produced no evidence of embryotoxicity in rats, post-implantation loss was elevated in all rabbit treatment groups (doses as low as 15 mg/kg/day, about 1/3 the mrhd on a mg/m2 basis). non-teratogenic

Propafenone Hydrochloride 150mg Film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

propafenone hydrochloride 150mg film-coated tablets

accord healthcare ireland ltd. - propafenone hydrochloride - film-coated tablet - 150 milligram(s) - antiarrhythmics, class ic; propafenone

Propafenone Hydrochloride 300mg Film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

propafenone hydrochloride 300mg film-coated tablets

accord healthcare ireland ltd. - propafenone hydrochloride - film-coated tablet - 300 milligram(s) - antiarrhythmics, class ic; propafenone

PMS-PROPAFENONE TABLET Canada - English - Health Canada

pms-propafenone tablet

pharmascience inc - propafenone hydrochloride - tablet - 150mg - propafenone hydrochloride 150mg - class ic antiarrythmics

PMS-PROPAFENONE TABLET Canada - English - Health Canada

pms-propafenone tablet

pharmascience inc - propafenone hydrochloride - tablet - 300mg - propafenone hydrochloride 300mg - class ic antiarrythmics

PMS-PROPAFENONE TABLET Canada - English - Health Canada

pms-propafenone tablet

pharmascience inc - propafenone hydrochloride - tablet - 150mg - propafenone hydrochloride 150mg - class ic antiarrythmics

PMS-PROPAFENONE TABLET Canada - English - Health Canada

pms-propafenone tablet

pharmascience inc - propafenone hydrochloride - tablet - 300mg - propafenone hydrochloride 300mg - class ic antiarrythmics

PMS-PROPAFENONE TABLET Canada - English - Health Canada

pms-propafenone tablet

pharmascience inc - propafenone hydrochloride - tablet - 150mg - propafenone hydrochloride 150mg - class ic antiarrythmics